Editas Medicine

discovery-phase pharmaceutical company

EDIT Nasdaq ISIN US28106W1036 SEC CIK 1650664 LEI 5299000AON4Q9NT2JE42
Follow Editas Medicine Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $10.4M +37.4% vs same quarter last year
Net income −$23.4M +6.9% vs same quarter last year
EPS, diluted −$0.15 +46.4% vs same quarter last year
Operating cash flow −$21.2M +31.3% vs same quarter last year
Revenue by quarter
$30.6M
$4.7M
$3.6M
$7.5M
$24.7M
$2.8M
$11.9M
$10.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income13 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$40.5M−$160.1M
FY24$32.3M−$237.1M
FY23$78.1M−$153.2M
FY22$19.7M−$220.4M
FY21$25.5M−$192.5M
FY20$90.7M−$116M
FY19$20.5M−$133.7M
FY18$31.9M−$110M
FY17$13.7M−$120.3M
FY16$6.1M−$97.2M
FY15-−$72.9M
FY14-−$13.7M
FY13--
MarginsShare of revenue
  • Operating margin
  • Net margin
−2000%−1500%−1000%−500%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−394.9%−395%
FY24−777.2%−733.7%
FY23−216.6%−196.1%
FY22−1146.3%−1118.3%
FY21−756.1%−753.6%
FY20−148.6%−127.8%
FY19−686.4%−651.4%
FY18−356.1%−344.3%
FY17−873.6%−876.5%
FY16−1605.6%−1605.5%
FY15--
FY14--
FY13--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$165.8M
FY24−$219.1M
FY23−$136.9M
FY22−$181.5M
FY21−$171.8M
FY20−$187M
FY19−$46.8M
FY18−$50.5M
FY17−$11.5M
FY16−$53.7M
FY15−$6.9M
FY14−$9.9M
FY13-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Editas Medicine
  • Healthcare median
−2000%−1500%−1000%−500%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearEditas MedicineHealthcare median
FY25−395%−30.6%
FY24−733.7%−47%
FY23−196.1%−58%
FY22−1118.3%−80.4%
FY21−753.6%−71.9%
FY20−127.8%−62.2%
FY19−651.4%−46.3%
FY18−344.3%−49.6%
FY17−876.5%−45.9%
FY16−1605.5%−36%
FY15-−38.4%
FY14-−35.5%
FY13-−37.1%